At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 22 enrolled
Drug / intervention
Sunitinib (Sutent) +1 moredrug
Likely dose
Sunitinib (Sutent) 37.5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Exploratory Evaluation Of A Sequential Administration Of Docetaxel And SU011248 In Women With Advanced Breast Cancer
In Brief
A Phase 1 clinical trial evaluating Sunitinib (Sutent) and Taxotere for Breast Neoplasms. Completed, enrolled 22 participants across 3 sites in 3 countries.
Detailed Summary
This study is to evaluate the safety of SU011248 (Sunitinib/Sutent) in combination with docetaxel in patients with metastatic or locally recurrent breast cancer who have not received chemotherapy treatment in the advanced disease setting.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Neoplasms
CountriesBelgium, Italy, Sweden
Collaborators--
Timeline
Phase 1CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 2006
Enrollment StartJul 2006
Primary CompletionOct 2008
Study CompletionFeb 2009
TodayJul 2026
First PostedFeb 14, 2006
Enrollment StartJul 1, 2006
Primary CompletionOct 1, 2008
Study CompletionFeb 1, 2009
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 20.4 years ago
Interventions
Sunitinib (Sutent)drug
Sunitinib (Sutent) 37.5 mg in schedule 2/1; Sunitinib (Sutent) 37.5 mg in continuous dosing (post discontinuation of axotere) and in accordance with Investigator decision
Taxoteredrug
Taxotere 75 mg/m2 iv, once every 3 weeks